Tocilizumab for severe COVID-19 in solid organ transplant recipients : a matched cohort study
© 2020 The American Society of Transplantation and the American Society of Transplant Surgeons..
The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID-19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID-19, 29 (24.8%) received tocilizumab. The 90-day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, P = .03). When compared to control patients matched by age, hypertension, chronic kidney disease, and administration of high dose corticosteroids, there was no significant difference in mortality (41% vs 28%, P = .27), hospital discharge (52% vs 72%, P = .26), or secondary infections (34% vs 24%, P = .55). Among patients who received tocilizumab, there was also no difference in mortality based on the level of oxygen support (intubated vs not intubated) at the time of tocilizumab initiation. In this matched cohort study, tocilizumab appeared to be safe but was not associated with decreased 90-day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID-19.
| Errataetall: |
CommentIn: Am J Transplant. 2021 Mar;21(3):911-912. - PMID 33641267 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons - 20(2020), 11 vom: 07. Nov., Seite 3198-3205 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Pereira, Marcus R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 23.12.2020 Date Revised 24.01.2023 published: Print-Electronic CommentIn: Am J Transplant. 2021 Mar;21(3):911-912. - PMID 33641267 Citation Status MEDLINE |
|---|
| doi: |
10.1111/ajt.16314 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM315181281 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM315181281 | ||
| 003 | DE-627 | ||
| 005 | 20231225154343.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ajt.16314 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1050.xml |
| 035 | |a (DE-627)NLM315181281 | ||
| 035 | |a (NLM)32946668 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pereira, Marcus R |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Tocilizumab for severe COVID-19 in solid organ transplant recipients |b a matched cohort study |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.12.2020 | ||
| 500 | |a Date Revised 24.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Am J Transplant. 2021 Mar;21(3):911-912. - PMID 33641267 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The American Society of Transplantation and the American Society of Transplant Surgeons. | ||
| 520 | |a The safety and efficacy of tocilizumab for the treatment of severe respiratory symptoms due to COVID-19 remain uncertain, in particular among solid organ transplant (SOT) recipients. Thus, we evaluated the clinical characteristics and outcomes of 29 hospitalized SOT recipients who received tocilizumab for severe COVID-19, compared to a matched control group who did not. Among a total of 117 total SOT recipients hospitalized with COVID-19, 29 (24.8%) received tocilizumab. The 90-day mortality was significantly higher among patients who received tocilizumab (41%) compared to those who did not (20%, P = .03). When compared to control patients matched by age, hypertension, chronic kidney disease, and administration of high dose corticosteroids, there was no significant difference in mortality (41% vs 28%, P = .27), hospital discharge (52% vs 72%, P = .26), or secondary infections (34% vs 24%, P = .55). Among patients who received tocilizumab, there was also no difference in mortality based on the level of oxygen support (intubated vs not intubated) at the time of tocilizumab initiation. In this matched cohort study, tocilizumab appeared to be safe but was not associated with decreased 90-day mortality. Larger randomized studies are needed to identify whether there are subsets of SOT recipients who may benefit from tocilizumab for treatment of COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a clinical research/practice | |
| 650 | 4 | |a complication: infectious | |
| 650 | 4 | |a immune regulation | |
| 650 | 4 | |a immunosuppression/immune modulation | |
| 650 | 4 | |a infectious disease | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Aversa, Meghan M |e verfasserin |4 aut | |
| 700 | 1 | |a Farr, Maryjane A |e verfasserin |4 aut | |
| 700 | 1 | |a Miko, Benjamin A |e verfasserin |4 aut | |
| 700 | 1 | |a Aaron, Justin G |e verfasserin |4 aut | |
| 700 | 1 | |a Mohan, Sumit |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Husain, Syed A |e verfasserin |4 aut | |
| 700 | 1 | |a Ratner, Lloyd E |e verfasserin |4 aut | |
| 700 | 1 | |a Arcasoy, Selim |e verfasserin |4 aut | |
| 700 | 1 | |a Uriel, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Elizabeth X |e verfasserin |4 aut | |
| 700 | 1 | |a Fox, Alyson N |e verfasserin |4 aut | |
| 700 | 1 | |a Tsapepas, Demetra S |e verfasserin |4 aut | |
| 700 | 1 | |a Emond, Jean C |e verfasserin |4 aut | |
| 700 | 1 | |a Verna, Elizabeth C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons |d 2001 |g 20(2020), 11 vom: 07. Nov., Seite 3198-3205 |w (DE-627)NLM119667924 |x 1600-6143 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g number:11 |g day:07 |g month:11 |g pages:3198-3205 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ajt.16314 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2020 |e 11 |b 07 |c 11 |h 3198-3205 | ||